Estimation of lifetime benefits from the optimization of secondary prevention in patients with established atherosclerotic cardiovascular disease - Scorecard - MDSpire
Advertisement
Estimation of lifetime benefits from the optimization of secondary prevention in patients with established atherosclerotic cardiovascular disease
Clinical Scorecard: Assessment of Long-Term Advantages from Enhanced Secondary Prevention in Individuals with Established Atherosclerotic Cardiovascular Disease
At a Glance
Category
Detail
Condition
Atherosclerotic cardiovascular disease (ASCVD)
Key Mechanisms
Modification of key risk factors including hypertension, hypercholesterolaemia, diabetes, and tobacco smoking to reduce recurrent cardiovascular events
Target Population
Patients with established ASCVD in Denmark, France, Germany, Italy, Poland, Spain, and the UK
Care Setting
Secondary prevention in clinical and population health settings across Europe
Key Highlights
Cardiovascular disease causes nearly four million deaths annually in Europe with a €282 billion economic burden.
Improving secondary prevention by optimizing control of hypertension, hypercholesterolaemia, diabetes, and smoking cessation to 70% treatment coverage can save over 94,000 cardiovascular-event-free life-years annually across seven European countries.
Significant gaps exist between guideline recommendations and real-world implementation of secondary prevention measures in ASCVD patients.
Guideline-Based Recommendations
Diagnosis
Use risk stratification tools such as the SMART risk score and EUROASPIRE risk model to assess recurrent event risk in ASCVD patients.
Management
Optimize treatment coverage for hypertension, hypercholesterolaemia, diabetes, and promote smoking cessation aiming for at least 70% of patients reaching treatment targets.
Implement proactive identification of at-risk patients and timely initiation of guideline-directed secondary prevention therapies.
Monitoring & Follow-up
Regularly monitor control of key risk factors and adherence to secondary prevention treatments to ensure sustained risk reduction.
Risks
Failure to control modifiable risk factors significantly increases risk of recurrent cardiovascular events and mortality in ASCVD patients.
Patient & Prescribing Data
Patients with established ASCVD across seven European countries
Increasing treatment coverage and smoking cessation rates from approximately 43% to 70% can substantially extend cardiovascular-event-free life-years at the population level.
Clinical Best Practices
Close the gap between clinical guidelines and real-world care by enhancing secondary prevention implementation.
Incorporate lifetime benefit estimations into shared decision-making to improve patient engagement and adherence.
Support national cardiovascular health plans and integrated care approaches to reduce inequalities in ASCVD outcomes.
Damon B. Dixon, MD, at Phoenix Children’s Cardiology, is the author to this EndoText chapter. Dr. Dixon brings nationally recognized expertise in pediatric cardiovascular risk assessment and non?invasive vascular imaging.
